Main Menu

RAIDER

A randomised phase II trial of adaptive image guided standard or dose escalated tumour boost radiotherapy in the treatment of transitional cell carcinoma of the bladder.

Disease sites: Bladder cancerurological cancers

Treatment modality: Radiotherapy

Status: Open to recruitment

Trial details

RAIDER is a phase II, international, parallel cohort, three arm, two stage randomised trial of adaptive tumour focused radiotherapy for bladder cancer. Stage I will investigate the feasibility of dose escalated tumour boost radiotherapy delivery at multiple centres and Stage II will assess long term side effects of this treatment. 

At least 240 participants with muscle invasive bladder cancer will be randomised to one of three treatment groups: standard radiotherapy, standard dose tumour focused adaptive radiotherapy and dose escalated tumour boost adaptive radiotherapy. Participants will have daily radiotherapy for 4 or 6 weeks (depending on standard regimen in use at their hospital) and will be followed up after treatment for a minimum of 5 years.

Further information

Chief Investigator: Dr Robert Huddart, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Dr Emma Hall

Trial management contact: [email protected]

ISRCTN: 26779187

Sponsor: The Institute of Cancer Research

Funding: Cancer Research UK (CRUK/14/016)

Further information including recruitment progress is available from the UKCRN portfolio

Publications and presentations

Lewis R, Hall E, Griffin C, Hafeez S, Huddart R. Current UK practice in organ sparing treatment of muscle invasive bladder cancer (MIBC) and impact on design of the RAIDER image guided radiotherapy (IGRT) trial. Presented at: 10th National Cancer Research Institute Cancer Conference; 2014 Nov 2-5; Liverpool, UK.

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.